Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Lipid-Lowering Therapy Without Aspirin vs. Moderate-Intensity Lipid-Lowering Therapy With Aspirin in Asymptomatic Patients With Coronary Artery Calcification
KCT0010414Phase 4Not yet recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of ulinastatin, aspirin in coronary arteriosclerosis, Coronary artery calcification (CAC), sponsored by JW Pharmaceutical Corporation. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
ulinastatinaspirin
03
Conditions
coronary arteriosclerosisCoronary artery calcification (CAC)
Beyond the preview
Go deeper on KCT0010414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010414.